secwatch.observer — SEC 8-K summary
======================================

Issuer:     Notable Labs, Ltd. (—)
CIK:        0001603207
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001493152-23-037344
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 5.02, 3.03, 5.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vascular Biogenics completes merger with Notable Labs; former Notable holders own 75.2% of combined co
--------------------------------------------------------------------------------

- Former Notable shareholders own ~75.2% of combined co on fully-diluted basis; ~8.94M shares outstanding post-merger.
- 1-for-35 reverse split and name change to Notable Labs, Ltd. effective Oct 16; ticker changes from VBLT to NTBL Oct 17.
- All prior directors resigned; new board appointed: Bock, Feinberg, Galen, Pätsi, Rice, Dubin, Graney. Bock named CEO, McPherson CFO, Wagner CSO.
- Company sold VB-601 asset to Immunewalk for $250k upfront plus up to $4.75M in milestones and royalties.
- New ticker NTBL; CUSIP M7517R107; company now a clinical-stage precision oncology platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603207/000149315223037344/0001493152-23-037344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603207/000149315223037344/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-037344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer